It has nearly been ten years since the Supreme Court’s landmark Mayo v. Prometheus (132 S.Ct. 1289 (2012)) decision, in which the Court established a two-prong test for determining patentable subject matter under 35 U.S.C. §...more
7/16/2020
/ Biotechnology ,
Judicial Exception ,
Mayo v. Prometheus ,
Patent Prosecution ,
Patent-Eligible Subject Matter ,
Patents ,
Pharmaceutical Industry ,
Pharmaceutical Patents ,
Product of Nature Doctrine ,
Section 101 ,
Treatment Method Patents ,
USPTO